Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 52-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of Lorcaserin Hydrochloride in Overweight and Obese Patients.

Trial Profile

A 52-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of Lorcaserin Hydrochloride in Overweight and Obese Patients.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lorcaserin (Primary)
  • Indications Obesity
  • Focus Registrational; Therapeutic Use
  • Acronyms BLOSSOM
  • Sponsors Arena Pharmaceuticals
  • Most Recent Events

    • 24 Oct 2017 Results (n=2483) of post-hoc analysis assessing changes in liver enzymes in patients treated with Lorcaserin for obesity from three pivotal trials (BLOSSOM, BLOOM and BLOOM-DM), presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases.
    • 17 Sep 2017 Results of a pooled analysis from BLOOM & BLOSSOM trials (n=5658) presented at the Council on Hypertension Scientific Session 2017
    • 17 Sep 2017 Results of a pooled cohort analysis from BLOOM, BLOSSOM, BLOOM-DM trials presented at the Council on Hypertension Scientific Session 2017
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top